B2M and renal cell carcinoma: Mechanistically, αKG treatment decreases H3K4me1 in the promoter regions of B2M, thus upregulating MHC‐I expression and enhancing CTLs‐mediated anti‐tumor effects in multiple types of cancer including RCC.